Previous Close | 32.98 |
Open | 33.15 |
Bid | 24.07 x 1100 |
Ask | 33.00 x 800 |
Day's Range | 32.54 - 34.30 |
52 Week Range | 21.99 - 39.09 |
Volume | |
Avg. Volume | 363,685 |
Market Cap | 1.871B |
Beta (5Y Monthly) | 0.97 |
PE Ratio (TTM) | 1,709.50 |
EPS (TTM) | 0.02 |
Earnings Date | May 07, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 40.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for SUPN
ROCKVILLE, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences: Jefferies Biotech on the Bay SummitDate:Tuesday, March 12, 2024Place:The 1 Hotel South Beach, Miami, Fla. Barclays Glob
In this piece, we will take a look at the 11 best small cap pharma stocks to invest in. If you want to skip our overview of the global pharmaceutical and healthcare industry, which is one the most unique sectors in the world, then you can check out 5 Best Small Cap Pharma Stocks to […]
Supernus Pharmaceuticals ( NASDAQ:SUPN ) Full Year 2023 Results Key Financial Results Revenue: US$607.5m (down 8.9...